US FDA Approved First Pill (Lipfendra) Replacing Injections for High Cholesterol

In Brief:

1. On July 16, 2026, the US FDA approved Lipfendra, the first pill to replace cholesterol injections.
2. Treats elevated cholesterol, including inherited hypercholesterolemia.
3. Improves patient compliance and cardiovascular outcomes over injections.
4. Delayed pending CDSCO regulatory approval and potential local trials.

On July 16, 2026, the US FDA approved Lipfendra, the first oral pill designed to replace injectable therapies for managing high cholesterol, including inherited hypercholesterolemia. By providing a far more convenient alternative to traditional injections, the medication is expected to significantly improve patient adherence and boost overall cardiovascular health outcomes.

However, its release in India remains distant, as Dr. Subhash Mandal of the Indian Pharmaceutical Association highlighted that the drug must first undergo Indian regulatory review with the CDSCO, which may include local clinical trials.